Rosa Maytin
Family · Jacksonville, FLNPI 1972068708
Payments from drug & device makers
Across 376 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$889
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$813
- Johnson & Johnson$763
- Neurocrine Biosciences, Inc.$694
- plus $4K from 15 others
What the payments were for
- Food & beverage$9,177100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $1,211 |
| Teva Pharmaceuticals USA, Inc. | 73 | $1,120 |
| AbbVie | 35 | $889 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $813 |
| Johnson & Johnson | 28 | $763 |
| Neurocrine Biosciences, Inc. | 24 | $694 |
| Alkermes, Inc. | 26 | $682 |
| Vanda Pharmaceuticals Inc. | 23 | $670 |
| Almatica Pharma LLC | 25 | $548 |
| Axsome Therapeutics, Inc. | 17 | $515 |
| Lundbeck LLC | 20 | $428 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $319 |
| E.r. Squibb & Sons, L.L.C. | 10 | $169 |
| Bausch Health US, LLC | 5 | $95 |
| Indivior Inc. | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Adlon Therapeutics L.p. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $19 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$450
- ABILIFY MAINTENA$363
- REXULTI$347
- INGREZZA$256
- ABILIFY ASIMTUFII$248
- SPRAVATO$143
- Fanapt$124
- CAPLYTA$118
- Auvelity$116
- ARISTADA INITIO$112
- VRAYLAR$103
How this compares
$9,177 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $33,100 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $32,405 |
| Abilify MaintenaAripiprazole | 11 | $30,520 |
| Lurasidone Hcl | 64 | $24,225 |
| ZoloftSertraline Hcl | 14 | $12,178 |
| TrintellixVortioxetine Hydrobromide | 19 | $10,421 |
| Aripiprazole | 79 | $9,246 |
| BelsomraSuvorexant | 20 | $9,053 |
| Quetiapine Fumarate | 456 | $6,848 |
| Paliperidone ErPaliperidone | 35 | $4,873 |
| RisperdalRisperidone | 13 | $4,659 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,551 |
| Clonazepam | 223 | $2,376 |
| Hydroxyzine Pamoate | 150 | $1,759 |
| Olanzapine | 103 | $1,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal | $763 | $37,75926 claims |
| Alkermes, Inc.Lybalvi | $682 | $32,40516 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,211 | $30,52011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $319 | $14,97330 claims |
| Almatica Pharma LLCSertraline Hcl | $548 | $1,534263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Jacksonville
- Leighanne MeadeJacksonville$98K
- Jori TaylorJacksonville$48K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.